MedTrace Logo

Moxonidine in Patients Undergoing Vascular Surgery

NCT00244504 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2009-11-10

No results posted yet for this study

Summary

Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion, patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day before surgery until day 4 after surgery. Holter-EKG for 48 h, starting just before surgery. Repeated 12-lead EKG, measurements of Troponin I and BNP, clinical visitations, follow-up interviews at 6 and 12 months

Conditions

  • Cardiac Disease
  • Vascular Surgery

Interventions

DRUG

moxonidine

moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Miodrag Filipovic, PD Dr. · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00244504 on ClinicalTrials.gov